Should You Think About Buying AdderaCare AB (STO:ADDERA) Now?HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Should You Think About Buying AdderaCare AB (STO:ADDERA) Now?Simply Wall StSimply Wall St.January 9, 2020ReblogShareTweetShareView photosAdderaCare AB (STO:ADDERA), which is in the medical equipment business, and is based in Sweden, saw a significant share price rise of over 20% in the past couple of months on the OM. As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value. Is there still an opportunity here to buy? Today I will analyse the most recent data on AdderaCare’s outlook and valuation to see if the opportunity still exists. See our latest analysis for AdderaCare Is AdderaCare still cheap?Great news for investors – AdderaCare is still trading at a fairly cheap price. In this instance, I’ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock’s cash flows. I find that AdderaCare’s ratio of 35.8x is below its peer average of 54.3x, which suggests the stock is undervalued compared to the Medical Equipment industry. What’s more interesting is that, AdderaCare’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.What does the future of AdderaCare look like?OM:ADDERA Past and Future Earnings, January 9th 2020MoreFuture outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With revenues expected to grow by a double-digit 14% over the next couple of years, the outlook is positive for AdderaCare. If the level of expenses is able to be maintained, it looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.What this means for you:Are you a shareholder? Since ADDERA is currently undervalued, it may be a great time to increase your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.Are you a potential investor? If you’ve been keeping an eye on ADDERA for a while, now might be the time to enter the stock. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy ADDERA. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on AdderaCare. You can find everything you need to know about AdderaCare in the latest infographic research report. If you are no longer interested in AdderaCare, you can use our free platform to see my list of over 50 other stocks with a high growth potential.If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextHere's What Absolent Group AB (publ)'s (STO:ABSO) P/E Is Telling UsSimply Wall St.Timeless Software (HKG:8028) Shareholders Have Enjoyed A 51% Share Price GainSimply Wall St.Is There Now An Opportunity In NetDragon Websoft Holdings Limited (HKG:777)?Simply Wall St.Imagine Owning CommsChoice Group (ASX:CCG) And Wondering If The 36% Share Price Slide Is JustifiedSimply Wall St.If You Had Bought Automated Systems Holdings (HKG:771) Stock A Year Ago, You'd Be Sitting On A 14% Loss, TodaySimply Wall St.Biocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoToronto Exchange Set to Re-Open After Glitch Forces Early CloseBloomberg'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video